11.53
-0.47 (-3.92%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Mixed |
| Medical Care Facilities (Global) | Bullish | Bullish | |
| Stock | COMPASS Pathways Plc - American | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.67 |
Select this tab to load the latest available analysis.
|
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 13.64% |
| % Held by Institutions | 55.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eagle Health Investments Lp | 30 Jun 2026 | 2,060,427 |
| Aisling Capital Management Lp | 30 Jun 2026 | 1,432,336 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |